Table 1.
Patient’s characteristics.
| Characteristics | All patients (N = 51) | Patients with irAEs (N = 24) | Patients with no irAEs (N = 27) |
|---|---|---|---|
| Age at diagnosis(year) | |||
| Median age (range) | 52 (22-77) | 54 (26-77) | 52 (22-71) |
| Gender, N (%) | |||
| Male | 34 (66.7) | 16 (66.7) | 18 (66.7) |
| Female | 17 (33.3) | 8 (33.3) | 9 (33.3) |
| Original site, N (%) | |||
| Esophagus | 12 (23.5) | 6 (25.0) | 6 (22.2) |
| Stomach | 17 (33.3) | 8 (33.3) | 9 (33.3) |
| Colorectum | 11 (21.6) | 5 (20.8) | 6 (22.2) |
| Others | 11 (21.6) | 5 (20.8) | 6 (22.2) |
| Treatment option, N (%) | |||
| anti-PD-1 | 33 (64.7) | 18 (75.0) | 15 (55.5) |
| anti-PD-L1 | 18 (35.3) | 6 (25.0) | 12 (44.5) |
| Best overall tumor response, N (%) | |||
| Partial Response | 13 (25.5) | 9 (37.5) | 4 (14.8) |
| Stable Disease | 11 (21.6) | 7 (29.2) | 4 (14.8) |
| Progressive Disease | 27 (52.9) | 8 (33.3) | 19 (70.4) |
| Response group, N (%) | |||
| Durable clinical benefit (DCB) | 19 (37.3) | 12 (50.0) | 7 (25.9) |
| No durable benefit (NDB) | 32 (62.7) | 12 (50.0) | 20 (74.1) |